Press Releases

Press Releases

Company news, development updates and public announcements from Tapanstech Therapeutics.

 

2026
2025

2026

Cambridge,Massachusetts-25th,May '26 CellantraTech Signs Strategic Agreement with NVIDIA to Accelerate AI-Driven Cancer Drug Discovery and Gene Therapy Development

Cambridge,Massachusetts-30th,April,'26 CellantraTech Announces Discovery of Novel KRAS G12D / HLA-C08 TCR Candidate for Precision Cancer Immunotherapy

Cambridge,Massachusetts-11th,Feb '26 CellantraTech Announces Discovery of Novel MAGE-C1-Targeting TCR Candidate for Cancer Immunotherapy

Cambridge,Massachusetts-15th,Jan '26 CellantraTech Files Patent Application Covering G059, a Proprietary Surface-Targeting Ligand for Precision Gene Delivery

2025

 

 

15th,Nov 2025-Cambridge,Massachusetts CellantraTech Files Patent Application Covering A20T013, an αvβ6-Binding Monobody Designed as a Modular Address Ligand for Gene Delivery

22th,Aug 2025-Cambridge,Massachusetts CellantraTech AND CAPSTAN SIGN COOPERATION MEMORANDUM TO ADVANCE IN VIVO CAR-T THERAPIES FOR SOLID TUMORS

Cambridge, Massachusetts— 15th,Jul 2025 CellantraTech Announces Discovery of Proprietary CardioFibros Target and Biomarker for Precision In Vivo Gene Therapy

Cambridge, Massachusetts— 5th,Jul 2025 CellantraTech Announces Discovery and Engineering of Potent HLA-A*11:01-Restricted KRAS G12V TCR Candidate

Cambridge, Massachusetts— 13th,Jun 2025 CellantraTech Announces Discovery and Invention of Novel KRAS G12C-Targeting TCR Candidate

Cambridge, Massachusetts— 3th,May 2025 CellantraTech Announces Discovery and Invention of Novel NY-ESO-1-Targeting TCR Candidate

Cambridge,Massachusetts-17th,Apr 2025 CellantraTech Announces Discovery and Invention of Novel HA-2-Targeting TCR-T Candidate for Hematologic Malignancies

Cambridge,Massachusetts-11th,Apr 2025 CellantraTech Announces Discovery and Invention of Novel HPV16 E7-Targeting TCR-T Candidate

Cambridge, Massachusetts— 30th,Feb 2025 CellentraTech Files Patent Application Covering W2993, Advancing Intellectual Property Strategy for Lead KRAS G12D Program

Cambridge, Massachusetts— 25th,Feb 2025 CellantraTech Signs Memorandum with Moderna to Advance mRNA Manufacturing Capabilities

Cambridge, Massachusetts— 25th,Jan 2025 Cellantra Announces Discovery of Potent Novel MAGE-C2-Targeting TCR Candidate for Cancer Immunotherapy

CellantraTech Therapeutics is a preclinical biotechnology company building a reusable nonviral delivery platform and two co-lead oncology programs.